Royalty Pharma (RPRX) Non-Current Debt (2019 - 2026)

Royalty Pharma has disclosed Non-Current Debt across 8 years of filings, most recently posting $8.6 billion for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $8.6 billion, up 29.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.6 billion (up 29.58% YoY), and the FY2025 annual result was $8.6 billion, up 29.57% from the prior year.
• Non-Current Debt came in at $8.6 billion for Q1 2026 at Royalty Pharma, roughly flat from $8.6 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $8.6 billion in Q1 2026 to a low of $6.1 billion in Q3 2022.
• The 5-year median for Non-Current Debt is $6.6 billion (2024), against an average of $6.9 billion.
• Across the five-year window, Non-Current Debt declined 13.78% in 2023 and increased 29.58% in 2025, its largest moves.
• Royalty Pharma's Non-Current Debt stood at $6.1 billion in 2022, then rose by 0.27% to $6.1 billion in 2023, then increased by 7.81% to $6.6 billion in 2024, then grew by 29.57% to $8.6 billion in 2025, then rose by 0.06% to $8.6 billion in 2026.
• The last three Non-Current Debt figures came in at $8.6 billion (Q1 2026), $8.6 billion (Q4 2025), and $8.6 billion (Q3 2025), per Business Quant data.